Long-term follow-up shows BRAF V600E mutation worsens outcomes in papillary thyroid carcinoma patients, indicating significant prognostic implications.
In this study the BRAF(V600E) mutation correlated with the worst outcome for PTC patients, who were not only at a higher risk not to be cured but also for death. In particular, the BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features.
No takes yet. Share an insight, caveat, or question.
Elisei et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: